No significant impact of obesity on outcomes in the luminal A-like, luminal B-like and HER2-positive subtypes, but significantly poorer disease-free survival (DFS) and Overall survival (OS) in severely obese compared with underweight/normal weight patients with triple-negative breast cancer. This evidence concerns the gene ERBB2 and obesity due to melanocortin 4 receptor deficiency.